Association of vitamin D receptor gene TaqI,FokI and ApaI variants with arteriovenous fistula failure in hemodialysis patients

Abstract

Purpose:

We investigated the influence of the vitamin D receptor gene TaqI (rs731236), ApaI (rs7975232), and FokI (rs2228570) polymorphisms in arteriovenous fistula failure in hemodialysis patients.

Methods:

This study was carried out with 54 patients who experienced two or more fistula failures in the late period after arteriovenous fistula operation and 58 control patients with no history of arteriovenous fistula failure in 3 years or longer. The polymerase chain reaction–restriction fragment length polymorphism method was used to determine the vitamin D receptor TaqI, FokI, and ApaI polymorphisms.

Results:

For vitamin D receptor gene TaqI and Fok1 polymorphisms, no significant association was found between the two groups (p > 0.05). However, a statistically significant association was determined for ApaI polymorphism between the two groups (p = 0.02). In patients, ApaI AA, AC, and CC genotype frequencies were found as 21 (38.9%), 32 (59.3%), and 1 (1.8%), respectively. However, genotype frequencies of AA, AC, and CC in the control group were 29 (50%), 22 (37.9%), and 7 (12.1%), respectively. In all three polymorphisms, no significant difference was found between the two groups in terms of allele frequencies (p > 0.05).

Conclusion:

Vitamin D receptor ApaI AC genotype may be a possible cardiovascular risk factor for the development of arteriovenous fistula failure.

Keywords

Vitamin D vitamin D receptor single nucleotide polymorphism arteriovenous fistula failure hemodialysis

Get full access to this article

View all access options for this article.

References

Koirala

Anvari

McLennan

Monitoring and surveillance of hemodialysis access. Semin Intervent Radiol 2016; 33(1): 25–30.

Hayashi

Huang

Nissenson

AR.

Vascular access for hemodialysis. Nat Clin Pract Nephrol 2006; 2(9): 504–513.

Al-Jaishi

Oliver

Thomas

et al . Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis 2014; 63(3): 464–478.

Holick

MF.

Vitamin D deficiency. N Engl J Med 2007; 357(3): 266–281.

Adams

Hewison

Update in vitamin D. J Clin Endocrinol Metab 2010; 95(2): 471–478.

Thacher

Clarke

BL.

Vitamin D insufficiency. Mayo Clin Proc 2011; 86(1): 50–60.

Rochel

Wurtz

Mitschler

et al . The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 2000; 5(1): 173–179.

Sato

Iwasaki

Kikkawa

et al . An efficacy of intensive vitamin D delivery to neointimal hyperplasia in recurrent vascular access stenosis. J Vasc Access 2016; 17(1): 72–77.

Santoro

Pellicanò

Cernaro

et al . Role of vitamin D in vascular complications and vascular access outcome in patients with chronic kidney disease. Curr Med Chem 2016; 23(17): 1698–1707.

10.

Kim

Park

Song

et al . Vitamin D: a possible modifying factor linking obesity to vascular calcification in hemodialysis patients. Nutr Metab 2017; 14(1): 27.

11.

Saab

Young

Gincherman

et al . Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007; 105(3): C132-C138.

12.

Wolf

Shah

Gutierrez

et al . Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72(8): 1004–1013.

13.

Koyama

Hirosawa

Anticoagulant effects of synthetic retinoids and activated vitamin D3. Semin Thromb Hemost 1998; 24(3): 217–226.

14.

Wasse

Huang

Naqvi

et al . Inflammation, oxidation and venous neointimal hyperplasia precede vascular injury from AVF creation in CKD patients. J Vasc Access 2012; 13(2): 168–174.

15.

Somjen

Weisman

Kohen

et al . 25-hydroxyvitamin D31alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005; 111(13): 1666–1671.

16.

Duque

Tabbara

Martinez

et al . Dialysis arteriovenous fistula failure and angioplasty: intimal hyperplasia and other causes of access failure. Am J Kidney Dis 2017; 69(1): 147–151.

17.

Krassilnikova

Ostrow

Bader

et al . Low dietary intake of vitamin D and vitamin D deficiency in hemodialysis patients. J Nephrol Ther 2014; 4(3): 166.

18.

Roy-Chaudhury

Spergel

Besarab

et al . Biology of arteriovenous fistula failure. J Nephrol 2007; 20(2): 150–163.

19.

Unnikrishnan

Huynh

Brott

et al . Turbulent flow evaluation of the venous needle during hemodialysis. J Biomech Eng 2005; 127(7): 1141–1146.

20.

Rotmans

Pasterkamp

Verhagen

HJM

et al . Hemodialysis access graft failure: time to revisit an unmet clinical need? J Nephrol 2005; 18(1): 9–20.

21.

Misra

Puggioni

et al . Increased shear stress with upregulation of VEGF-A and its receptors and MMP-2, MMP-9, and TIMP-1 in venous stenosis of hemodialysis grafts. Am J Physiol Heart Circ Physiol 2008; 294(5): H2219–H2230.

22.

Stracke

Konner

Köstlin

et al . Increased expression of TGF-beta1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas. Kidney Int 2002; 61(3): 1011–1019.

23.

Misra

Anderson

et al . The rat femoral arteriovenous fistula model: increased expression of matrix metalloproteinase-2 and -9 at the venous stenosis. J Vasc Interv Radiol 2008; 19(4): 587–594.

24.

Wasse

Huang

Long

et al . Very high-dose cholecalciferol and arteriovenous fistula maturation in ESRD: a randomized, double-blind, placebo-controlled pilot study. J Vasc Access 2014; 15(2): 88–94.

25.

Dusso

Brown

Slatopolsky

et al . Vitamin D. Am J Physiol Renal Physiol 2005; 289(1): F8–F28.

26.

Targher

Pichiri

Lippi

et al . Vitamin D, thrombosis, and hemostasis: more than skin deep. Semin Thromb Hemost 2012; 38(1): 114–124.

27.

Bikle

Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009; 94(1): 26–34.

28.

Lindqvist

Epstein

Olsson

Does an active sun exposure habit lower the risk of venous thrombotic events? A D-lightful hypothesis. J Thromb Haemost 2009; 7(4): 605–610.

29.

Beer

Venner

Ryan

et al . High dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol 2006; 135(3): 392–394.

30.

Khademvatani

Seyyed-Mohammadzad

Akbari

et al . The relationship between vitamin D status and idiopathic lower-extremity deep vein thrombosis. Int J Gen Med 2014; 7: 303–309.

31.

Pourfarzam

Nia

Atapour

et al . The influence of BsmI and TaqI vitamin D receptor gene polymorphisms on the intensity of hyperparathyroidism in Iranian hemodialysis patients. Adv Biomed Res 2014; 3(1): 213.

32.

Yang

Fan

et al . Associations among four polymorphisms (BsmI, FokI, TaqI and ApaI) of vitamin D receptor gene and end-stage renal disease: a meta-analysis. Arch Med Res 2015; 46(1): 1–7.

33.

Martin

McKnight

Patterson

et al . A rare haplotype of the vitamin D receptor gene is protective against diabetic nephropathy. Nephrol Dial Transplant 2010; 25(2): 497–503.

34.

Agarwal

Vasquez

Penagaluru

et al . Treatment of vitamin D deficiency/insufficiency with ergocalciferol is associated with reduced vascular access dysfunction in chronic hemodialysis patients. Hemodial Int 2015; 19(4): 499–508.

35.

Van Ballegooijen

Zelnick

Hoofnagle

et al . Association of vitamin D metabolites with arterial function in the hemodialysis fistula maturation study. Am J Kidney Dis 2017; 69(6): 805–814.

36.

Verschuren

Ocak

Dekker

et al . Candidate gene analysis of arteriovenous fistula failure in hemodialysis patients. Clin J Am Soc Nephrol 2013; 8(8): 1358–1366.

37.

Garrancho

Kirchgessner

Arranz

et al . Haemoglobin level and vascular access survival in haemodialysis patients. Nephrol Dial Transplant 2005; 20(11): 2453–2457.

38.

Gheith

Kamal

MM.

Risk factors of vascular access failure in patients on hemodialysis. Iran J Kidney Dis 2008; 2(4): 201–207.

39.

Jeong

Kim

et al . Administration of a high-dose erythropoietin-stimulating agent in hemodialysis patients is associated with late arteriovenous fistula failure. Yonsei Med J 2017; 58(4): 793–799.

40.

Chen

Chien

Chen

et al . Angiotensin converting-enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers are associated with prolonged vascular access patency in uremic patients undergoing hemodialysis. PLoS ONE 2016; 11(11): E0166362.

41.

Zadeh

Mohammadipour

Omrani

Correlation between CRP and early failure of arteriovenous fistula (AVF). Med J Islam Repub Iran 2015; 29: 219.

42.

Kats

Hawxby

Barker

et al . Impact of obesity on arteriovenous fistula outcomes in dialysis patients. Kidney Int 2007; 71(1): 39–43.

43.

Ben-Shoshan

Amir

Dang

et al . 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther 2007; 6(4): 1433–1439.

44.

Misra

Puggioni

et al . Increased expression of hypoxia-inducible factor-1 alpha in venous stenosis of arteriovenous polytetrafluoroethylene grafts in a chronic renal insufficiency porcine model. J Vasc Interv Radiol 2008; 19(2 Pt 1): 260–265.

45.

Candan

Yildiz

Kayataş

Role of the VEGF 936 gene polymorphism and VEGF-A levels in the late-term arteriovenous fistula thrombosis in patients undergoing hemodialysis. Int Urol Nephrol 2014; 46(9): 1815–1823.

46.

Zohny

Abd el-Fattah

Evaluation of circulating vascular endothelial growth factor and soluble adhesion molecules as reliable predictors of native arteriovenous fistula thrombosis in chronic hemodialysis patients. Clin Biochem 2008; 41(14–15): 1175–1180.

47.

Coussens

Timms

Boucher

et al . 1alpha,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection. Immunology 2009; 127(4): 539–548.

48.

Lin

Yang

Chung

et al . Functional polymorphisms in matrix metalloproteinases-1, -3, -9 are associated with arteriovenous fistula patency in hemodialysis patients. Clin J Am Soc Nephrol 2010; 5(10): 1805–1814.

49.

Ren

Zhao

et al . The impact of 1,25-dihydroxy vitamin D3 on the expressions of vascular endothelial growth factor and transforming growth factor-β₁ in the retinas of rats with diabetes. Diabetes Res Clin Pract 2012; 98(3): 474–480.

50.

Ikegaya

Yamamoto

Takeshita

et al . Elevated erythropoietin receptor and transforming growth factor-beta1 expression in stenotic arteriovenous fistulae used for hemodialysis. J Am Soc Nephrol 2000; 11(5): 928–935.

51.

Heine

Ulrich

Sester

et al . Transforming growth factor beta1 genotype polymorphisms determine AV fistula patency in hemodialysis patients. Kidney Int 2003; 64(3): 1101–1107.